Next Article in Journal
Clinicopathologic Characteristics, Survival, and Treatments for Gastric Adenosquamous Carcinoma: A Population-Based Study
Previous Article in Journal
The Abscopal Effect in Head-and-Neck Squamous Cell Carcinoma Treated with Radiotherapy and Nivolumab: A Case Report and Literature Review
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cancer-Related Lymphedema: Clinical Pearls for Providers

1
Department of Family Medicine, Secondary Care and Oncology Departments, McGill University Health Centre, and McGill University, Montreal, QC, Canada
2
McGill University Health Centre, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(6), 336-340; https://doi.org/10.3747/co.27.7225
Submission received: 2 September 2020 / Revised: 7 October 2020 / Accepted: 5 November 2020 / Published: 1 December 2020

Abstract

Lymphedema is a chronic inflammatory condition that results from damage to the lymphatic system. Lymphedema is classified as either primary or secondary, the former being caused by a malformation of lymph vessels or nodes, and the latter resulting from trauma, chronic lymphatic system overload, or the sequelae of cancer treatments. In the present article, we focus on secondary cancer-related lymphedema (CRL), a potential survivorship treatment-related effect. Treatments for breast, gynecologic, prostate, and head-and-neck cancers, and melanoma and other skin cancers are most frequently associated with CRL. The incidence of CRL varies widely based on cancer location and treatment modalities, with estimates ranging from 5% to 83% in various cancers. Given the lack of a universal definition and diagnostic criteria, the prevalence of CRL is difficult to ascertain; current estimates suggest that more than 300,000 Canadians are affected by CRL. Here, we present an overview of CRL, divided into 5 subtopics: lymphedema risk factors; early identification and intervention; diagnosis and staging; management, with emphasis on the volume reduction and maintenance phases, plus patient support and education; and clinical pearls to help providers integrate knowledge about CRL into their practice.
Keywords: cancer-related lymphedema; lymphatic therapy; cancer survivorship; patient self-management; general practitioners in oncology cancer-related lymphedema; lymphatic therapy; cancer survivorship; patient self-management; general practitioners in oncology

Share and Cite

MDPI and ACS Style

Chaput, G.; Ibrahim, M.; Towers, A. Cancer-Related Lymphedema: Clinical Pearls for Providers. Curr. Oncol. 2020, 27, 336-340. https://doi.org/10.3747/co.27.7225

AMA Style

Chaput G, Ibrahim M, Towers A. Cancer-Related Lymphedema: Clinical Pearls for Providers. Current Oncology. 2020; 27(6):336-340. https://doi.org/10.3747/co.27.7225

Chicago/Turabian Style

Chaput, G., M. Ibrahim, and A. Towers. 2020. "Cancer-Related Lymphedema: Clinical Pearls for Providers" Current Oncology 27, no. 6: 336-340. https://doi.org/10.3747/co.27.7225

APA Style

Chaput, G., Ibrahim, M., & Towers, A. (2020). Cancer-Related Lymphedema: Clinical Pearls for Providers. Current Oncology, 27(6), 336-340. https://doi.org/10.3747/co.27.7225

Article Metrics

Back to TopTop